4//SEC Filing
Stephan Dietrich A 4
Accession 0001104659-23-087887
CIK 0001173281other
Filed
Aug 3, 8:00 PM ET
Accepted
Aug 4, 4:39 PM ET
Size
10.0 KB
Accession
0001104659-23-087887
Insider Transaction Report
Form 4
Stephan Dietrich A
DirectorPresident and CEO10% Owner
Transactions
- Exercise/Conversion
Stock option (right to buy)
2023-08-02−93,234→ 0 totalExercise: $0.02From: 2019-07-12Exp: 2023-12-31→ Common Stock (93,234 underlying) - Exercise/Conversion
Common Stock
2023-08-02$0.02/sh+93,234$2,051→ 93,234 total
Holdings
- 7,650
Common Stock
- 73,588
Common Stock
- 63,690(indirect: See footnote)
Common Stock
Footnotes (4)
- [F1]Shares held by the reporting person as a tenant by the entirety with his spouse.
- [F2]These shares are held in an irrevocable trust in which the spouse of the reporting person is the investment trustee, and the spouse and the descendants of the reporting person are its beneficiaries, and another irrevocable trust in which the reporting person is the investment trustee, and the reporting person and the descendants of the reporting person's spouse are its beneficiaries.
- [F3]Effective on June 14, 2023, NeuBase Therapeutics, Inc. conducted a reverse stock split at a ratio of 1-for-20 (the "Reverse Split"). The numbers of shares reported herein reflect the numbers of shares after the Reverse Split.
- [F4]Reflects stock options under NeuBase Therapeutics, Inc.'s 2018 Equity Incentive Plan.
Documents
Issuer
NeuBase Therapeutics, Inc.
CIK 0001173281
Entity typeother
Related Parties
1- filerCIK 0001774588
Filing Metadata
- Form type
- 4
- Filed
- Aug 3, 8:00 PM ET
- Accepted
- Aug 4, 4:39 PM ET
- Size
- 10.0 KB